HARROW INC (HROW)
US4158581094 - Common Stock
Taking everything into account, HROW scores 4 out of 10 in our fundamental rating. HROW was compared to 194 industry peers in the Pharmaceuticals industry. While HROW seems to be doing ok healthwise, there are quite some concerns on its profitability. HROW is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one!
1. Profitability
1.1 Basic Checks
HROW had negative earnings in the past year.
In the past year HROW had a positive cash flow from operations.
In the past 5 years HROW reported 4 times negative net income.
Of the past 5 years HROW 4 years had a positive operating cash flow.
1.2 Ratios
The Return On Assets of HROW (-9.50%) is better than 70.31% of its industry peers.
With a Return On Equity value of -57.62%, HROW perfoms like the industry average, outperforming 53.13% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -9.5% | ||
| ROE | -57.62% | ||
| ROIC | N/A |
ROA(3y)-11.86%
ROA(5y)-8.23%
ROE(3y)-83.03%
ROE(5y)-52.16%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
HROW's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 72.56%, HROW is in the better half of the industry, outperforming 78.13% of the companies in the same industry.
In the last couple of years the Gross Margin of HROW has grown nicely.
The Profit Margin and Operating Margin are not available for HROW so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 72.56% |
OM growth 3Y-25.96%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.41%
GM growth 5Y2.98%
2. Health
2.1 Basic Checks
HROW does not have a ROIC to compare to the WACC, probably because it is not profitable.
HROW has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, HROW has more shares outstanding
The debt/assets ratio for HROW has been reduced compared to a year ago.
2.2 Solvency
HROW has an Altman-Z score of 3.04. This indicates that HROW is financially healthy and has little risk of bankruptcy at the moment.
With a decent Altman-Z score value of 3.04, HROW is doing good in the industry, outperforming 73.44% of the companies in the same industry.
The Debt to FCF ratio of HROW is 60.96, which is on the high side as it means it would take HROW, 60.96 years of fcf income to pay off all of its debts.
With a decent Debt to FCF ratio value of 60.96, HROW is doing good in the industry, outperforming 77.08% of the companies in the same industry.
HROW has a Debt/Equity ratio of 3.21. This is a high value indicating a heavy dependency on external financing.
HROW has a Debt to Equity ratio of 3.21. This is amonst the worse of the industry: HROW underperforms 83.85% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 3.21 | ||
| Debt/FCF | 60.96 | ||
| Altman-Z | 3.04 |
ROIC/WACCN/A
WACC9.19%
2.3 Liquidity
HROW has a Current Ratio of 1.55. This is a normal value and indicates that HROW is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.55, HROW is not doing good in the industry: 73.44% of the companies in the same industry are doing better.
A Quick Ratio of 1.44 indicates that HROW should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.44, HROW is doing worse than 69.79% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.55 | ||
| Quick Ratio | 1.44 |
3. Growth
3.1 Past
HROW shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -106.67%.
The Revenue has grown by 48.15% in the past year. This is a very strong growth!
HROW shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 25.77% yearly.
EPS 1Y (TTM)-106.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.69%
Revenue 1Y (TTM)48.15%
Revenue growth 3Y38.63%
Revenue growth 5Y25.77%
Sales Q2Q%43.76%
3.2 Future
The Earnings Per Share is expected to grow by 58.43% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 35.32% on average over the next years. This is a very strong growth
EPS Next Y42.45%
EPS Next 2Y85.1%
EPS Next 3Y87.92%
EPS Next 5Y58.43%
Revenue Next Year53.63%
Revenue Next 2Y51.1%
Revenue Next 3Y52.7%
Revenue Next 5Y35.32%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
HROW reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 41.12, the valuation of HROW can be described as expensive.
Based on the Price/Forward Earnings ratio, HROW is valued a bit cheaper than the industry average as 73.96% of the companies are valued more expensively.
HROW's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 23.56.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 41.12 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of HROW indicates a somewhat cheap valuation: HROW is cheaper than 73.96% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of HROW indicates a somewhat cheap valuation: HROW is cheaper than 77.08% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 506.32 | ||
| EV/EBITDA | 477.87 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as HROW's earnings are expected to grow with 87.92% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y85.1%
EPS Next 3Y87.92%
5. Dividend
5.1 Amount
No dividends for HROW!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
HARROW INC
NASDAQ:HROW (11/21/2024, 2:08:06 PM)
43.395
+0.96 (+2.25%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.55B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 41.12 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -9.5% | ||
| ROE | -57.62% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 72.56% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.48
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 3.21 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.55 | ||
| Quick Ratio | 1.44 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-106.67%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y42.45%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)48.15%
Revenue growth 3Y38.63%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y